Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00410761 · OUTCOME

Overall Survival (OS)

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer · Source last updated 2025-09-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
From date of randomization until death, up to approximately 105 months

What was measured

OS is defined as the time from the date of randomization until death.

Groups in this outcome

Vandetanib 300 mg

Vandetanib (300 mg daily)

Placebo

Placebo daily

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Vandetanib 300 mg231
Placebo100

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Vandetanib 300 mg81.6Not reported64.698.5Not reported
Placebo80.4Not reported52.5NANA indicates that the upper limit of confidence interval was not estimable due to insufficient number of participants with events.
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        64.6
        upper Limit
        98.5
        value
        81.6
      2. comment
        NA indicates that the upper limit of confidence interval was not estimable due to insufficient number of participants with events.
        group Id
        OG001
        lower Limit
        52.5
        upper Limit
        NA
        value
        80.4
denoms
  1. counts
    1. group Id
      OG000
      value
      231
    2. group Id
      OG001
      value
      100
    units
    Participants
description
OS is defined as the time from the date of randomization until death.
dispersion Type
95% Confidence Interval
groups
  1. description
    Vandetanib (300 mg daily)
    id
    OG000
    title
    Vandetanib 300 mg
  2. description
    Placebo daily
    id
    OG001
    title
    Placebo
param Type
MEDIAN
reporting Status
POSTED
time Frame
From date of randomization until death, up to approximately 105 months
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice